Leading ICU Physician Describes Benefit of Risk Analysis, Prevention Measures, in Acute Kidney Injury test

Leading ICU Physician Describes Benefit of Risk Analysis, Prevention Measures, in Acute Kidney Injury test

Nov 30, 2017

A new article in the health care industry journal The Pathologist describes how the biomarkers in Ortho’s VITROS® NEPRHOCHECKTM  assay work to detect risk of acute kidney injury.  
 
“Tests that allow earlier diagnosis of AKI [such as those that use biomarkers TIMP-2 and IGFBP7] provide an opportunity to intervene earlier and have great potential to improve the short and long-term prognosis [for hospital patients],” writes Dr. Marlies Ostermann, a consultant in Critical Care and Nephrology at Guy’s and St Thomas’ Foundation Trust, and honorary senior lecturer at King’s College in London. “Prevention of severe AKI is associated with a shorter stay in hospital, a reduced risk of needing renal replacement therapy or treatment in the intensive care unit, and a decreased risk of developing chronic kidney disease, including end-stage renal failure.”
 
Read her full article in The Pathologist.
 
Read more about VITROS NEPRHOCHECK.

${loading}